Luca D. N.
- Country
- Italy
- Department
- Nefrology
Research Overview
- Evaluation of Finerenone, Dapagliflozin, and Ambrisentan in Biomarker-Guided Treatment of Chronic Kidney Disease-Associated Albuminuria
- Evaluation of Finerenone and Semaglutide for Albuminuria Reduction in Patients with Chronic Kidney Disease
- Evaluation of Zibotentan and Dapagliflozin Combination Versus Dapagliflozin Monotherapy in Chronic Kidney Disease with High Proteinuria: A Phase III Randomized Study
Data & Insights
Has run more than one trial at 12 of 100 partner sites.
Specializations
Chronic Kidney Disease Management
The investigator specializes in studying progressive chronic kidney disease (CKD) with particular emphasis on novel therapeutic approaches to slow disease progression and reduce proteinuria.
- Adaptive platform trials for CKD therapy
- Combination therapy approaches
- Standard of care optimization
Research focuses on evaluating multiple therapeutic agents for their effectiveness in reducing the decline of kidney function.
Biomarker Research
The investigator conducts innovative research in biomarker-targeted treatment approaches for kidney disease, including studies of urinary clusterin and EGF as diagnostic tools.
- Biomarker validation studies
- Personalized treatment strategies
- Response-guided therapy
Their work aims to develop more precise and individualized treatment approaches for CKD patients.
Specialized Nephrology Conditions
The investigator has expertise in treating specific kidney conditions, particularly IgA Nephropathy and CKD with high proteinuria.
- Novel therapeutic agents
- Disease-specific interventions
- Albuminuria reduction strategies
Research encompasses both established and experimental treatments for specific nephrology conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.